Description
PrymaLab · Research Use Only
Chonluten Peptide
Glu-Asp-Gly tripeptide · bronchial mucosa bioregulator
Chonluten peptide is a lyophilized vial of the tripeptide Glu-Asp-Gly, written EDG, assigned to lung and bronchial mucosa in the Khavinson bioregulator range. Its sequence is Epitalon with the amino-terminal alanine removed, which is the most useful thing to know about verifying it.
Specification Table
| Property | Value |
|---|---|
| Compound | Chonluten |
| Sequence designation | EDG |
| Amino acid sequence | Glutamate-Aspartate-Glycine |
| Sequence provenance | Secondary sources, converging. Not traced to a single primary citation. Confirm against the lot certificate before relying on it for calculation |
| Residue count | 3 |
| Molecular weight, calculated | 319.3 g/mol, computed from standard residue masses plus water rather than quoted from a paper |
| Truncation relationship | Identical to Epitalon (Ala-Glu-Asp-Gly) with the amino-terminal alanine removed |
| Net charge at neutral pH | Negative, two acidic residues against no basic residue |
| Smallest tripeptide in the range | Yes, at roughly 319.3 |
| Oxidation-prone residues | None |
| Chromophore | None. Concentration cannot be determined by 280 nm absorbance |
| Compound class | Short peptide bioregulator, cytogen subclass |
| Source tissue of the parent fraction | Lung and bronchial mucosa |
| Originating programme | St Petersburg Institute of Bioregulation and Gerontology |
| Proposed mechanism in the literature | Sequence-specific interaction with DNA, modulating tissue-associated gene expression |
| Mechanism status | Hypothesis. Not independently established outside the originating programme |
| Receptor | None identified |
| Appearance | White lyophilized powder |
| Purity | Per lot-specific certificate of analysis |
| Solubility | Water soluble |
| Storage, lyophilized | 2-8°C or -20°C, protected from light and moisture |
| Regulatory status | No approved human or veterinary formulation in any jurisdiction |
Why Is Chonluten Peptide Epitalon Minus One Residue?
This relationship is the single most practically useful fact about the compound and no supplier page appears to state it.
Epitalon is Ala-Glu-Asp-Gly. Chonluten peptide is Glu-Asp-Gly. Strip the amino-terminal alanine from the first and the second is what remains.
Because solid-phase synthesis assembles a chain from the carboxy terminus backwards, that alanine is the final residue added when producing Epitalon. A coupling that fails at the last step delivers Chonluten instead.
Epitalon is among the most widely sold compounds in this whole family, which means a great deal of Epitalon is being synthesised, and incomplete final couplings are a routine defect rather than a rare one.
Chonluten is therefore a plausible impurity in Epitalon preparations, and Epitalon a plausible impurity in Chonluten preparations where both are made in the same facility.
Pinealon and Cardiogen stand in exactly the same relationship. Two des-alanine pairs across one compound family is a structural pattern with a direct quality-control consequence.
How Should Chonluten Peptide Be Verified?
The truncation turns a general purity question into two specific ones that any supplier can answer.
Does the mass spectrum show a species near 390.4 alongside the expected 319.3? That 71 dalton difference is the alanine, and it is far too large for any instrument to miss if someone looks.
Does the chromatogram show a peak at the Epitalon retention time? Epitalon is slightly more hydrophobic by one alanine and elutes later, so a competent gradient separates them.
Both questions name the specific contaminant most likely to be present, which is worth more than a purity percentage that says nothing about what the remaining fraction actually is.
At roughly 319.3 daltons Chonluten peptide is the smallest tripeptide in this range, which makes it retain very poorly on a standard reversed-phase gradient. Ask what method was used before reading a purity figure at all.
Counterion identity matters disproportionately at this molecular weight. A single trifluoroacetate at 114 daltons is over 26 percent of the associated mass, among the largest corrections in the catalogue.
What Is a Bronchial Mucosa Bioregulator?
Two compounds in this family are assigned to respiratory tissue, and distinguishing them is the point of the phrasing.
Bronchogen is assigned to bronchial tissue itself, while Chonluten peptide is assigned to lung and bronchial mucosa, which means the epithelial lining rather than the structural tissue underneath it.
That distinction is finer than the organ names elsewhere in the family, where liver, heart and pancreas are unambiguous. Here two compounds share a broad anatomical region and are separated by tissue layer.
For search purposes it matters because people looking for a lung compound will find Bronchogen, and people looking specifically for a mucosal one should find this page. The two should not compete for the same term.
For the tissue-specificity claim it raises the bar considerably. Asserting that a tripeptide addresses bronchial mucosa specifically, as distinct from bronchial tissue generally, is a finer claim than any tissue-distribution study in this literature could currently support.
No such study exists across the family, so the mucosal assignment rests on the fractionation source rather than on demonstrated localisation.
What Chonluten Peptide Benefits Have Been Measured?
The published endpoints are narrower than the phrasing and worth stating precisely.
Work from the originating programme reports respiratory tissue observations in aged rodent models, including histological assessment and markers of tissue-associated gene expression.
Family-wide cell-culture work reports chromatin decondensation, advanced in support of the DNA-binding hypothesis rather than of any respiratory claim specifically.
The primary record for Chonluten is thinner than for Epitalon, Vilon or Pinealon, which are the most studied members of the range within the programme.
No well-powered independent Western clinical trial exists for this compound, which characterises the whole literature rather than this compound alone.
Chemistry settled, research record documented, mechanism unresolved. Holding those three apart is what separates a defensible statement from an inherited one.
What Chonluten Dosage and Delivery Figures Are Published?
Everything below comes from a published study in whichever species that study used.
Rodent work sits in the microgram per kilogram band by parenteral routes, matching the family.
The Russian clinical record describes ten to twenty day courses at tens to low hundreds of micrograms, given as discrete blocks.
Sublingual preparations appear specifically in the Chonluten literature, described as lingual drops, which is a delivery route the injectable-focused secondary sources rarely mention.
Figures from a sublingual route are not comparable with parenteral ones without accounting for absorption, and the family literature frequently omits which route a given number came from.
Nothing in the record fixes a receptor affinity, which leaves wide concentration ranging as a requirement here rather than a refinement.
How Should Chonluten Peptide Research Be Controlled?
With no receptor and an unresolved mechanism, controls carry the weight binding data would normally carry.
An Epitalon arm is the control this compound uniquely calls for. Since Chonluten peptide is Epitalon minus one residue, running both at matched molar concentration tests whether that single alanine does anything at all.
That comparison doubles as a specificity control and as a test of the programme claim, because the two compounds are assigned to entirely different tissues despite differing by one residue.
A reversed-sequence arm addresses specificity separately. Gly-Asp-Glu has identical composition and mass to Glu-Asp-Gly, differing only in order.
Free amino acid arms distinguish an effect of the intact tripeptide from an effect of glutamate, aspartate and glycine separately after hydrolysis.
For the DNA-binding proposal, calorimetry or surface plasmon resonance against immobilised oligonucleotides measures association directly instead of inferring it from a downstream expression change.
How Should the Vial Be Handled?
Chonluten peptide is chemically undemanding, and the notes are short.
No cysteine, no methionine and no tryptophan, which leaves the routes that degrade most peptides entirely unavailable.
Keep dry powder sealed against light and moisture at 2 to 8 degrees Celsius or below.
Water solubility is good, helped by two acidic residues and no basic residue at all, so run diluent gently down the vial wall and swirl.
Standard consumables are adequate. Unlike Cardiogen and Pinealon, this peptide carries a net negative charge and does not adsorb appreciably to ordinary plasticware.
Log the lot, measured mass, whether an Epitalon peak was looked for, counterion, net peptide content, diluent, volume, concentration and date.
A last note on why the Epitalon comparison is worth running properly rather than casually. Epitalon is the most commercially prominent compound in this entire family and carries by far the thickest primary record.
If a three-residue truncation of it behaves indistinguishably in a matched assay, that finding travels much further than any result obtained on Chonluten alone would.
If it behaves differently, that is direct evidence for the terminal-residue claim the programme has asserted for five decades without testing it head to head.
Either outcome is publishable, the material costs almost nothing, and the experiment fits on one plate.
A final note on the two respiratory compounds and how to stock them. Because Bronchogen and Chonluten are assigned to adjacent tissue, laboratories often buy both, and the two are easy to confuse on a shelf.
Their masses are not close, at roughly 446.5 and 319.3 respectively, so identification is straightforward once anyone measures. The confusion is entirely at the labelling stage rather than the analytical one.
Writing EDG and AEDL on the respective tubes solves it permanently and costs nothing.
That habit pays off across this whole family, where several compounds differ by a single residue and trade names carry no structural information at all.
One last observation on the tripeptides generally. Chonluten, Cartalax, Vesugen and Pinealon are all three residues, and between them they cover both series openings and three different terminal residues.
That subset alone would make a serviceable comparison panel, at a combined material cost lower than a single vial of most compounds elsewhere in this catalogue.
The barrier to testing this family properly has never been money.
It has been the absence of anyone treating the sequence set as the experimental design it plainly is.
Four vials, one afternoon, and a question that has been open since the 1970s would finally have a head-to-head answer rather than an assertion behind it.
Published Literature
References verified against the publisher record. This literature originates almost entirely from one research programme.
- Khavinson VK, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Karger, Basel; 2005.
- Khavinson VK. Neuroendocrinology Letters. 2002;23(Suppl 3):11-144.
- Anisimov VN, Khavinson VK. Critical Reviews in Oncology/Hematology. 2010;74(1):46-66.
- Fedoreyeva LI, Kireev II, Khavinson VK, Vanyushin BF. Biochemistry (Moscow). 2011;76(11):1210-1219.
- Khavinson VK, Solovyov AY, Zhilinsky DV, Shataeva LK, Bandaletova TY. Bulletin of Experimental Biology and Medicine. 2012;153(4):500-505.
Frequently Asked Questions
What is Chonluten peptide?
A lyophilized vial of the tripeptide Glu-Asp-Gly, written EDG, assigned to lung and bronchial mucosa in the Khavinson bioregulator range. For laboratory research alone, and not approved for any use in any jurisdiction.
How does it relate to Epitalon?
It is Epitalon with the amino-terminal alanine removed. Epitalon is Ala-Glu-Asp-Gly and Chonluten is Glu-Asp-Gly, so the two differ by exactly one residue at the front of the chain.
Why does that matter?
Because solid-phase synthesis builds from the carboxy terminus backwards, so alanine is the final residue added when making Epitalon. A failed last coupling delivers Chonluten instead.
Is Epitalon widely made?
It is among the most widely sold compounds in this family, so a great deal of it is being synthesised. Combined with incomplete final couplings being a routine defect, that makes the impurity route a real one.
How would contamination show up?
As a mass spectrum species near 390.4 alongside the expected 319.3, that 71 dalton gap being the alanine. Or as a chromatogram peak at the Epitalon retention time, which elutes slightly later.
Why is the chromatography method worth asking about?
Because at roughly 319.3 daltons this is the smallest tripeptide in the range and it retains very poorly on a standard reversed-phase gradient. A purity figure from a default method measures very little.
How large is the counterion correction?
At 319.3 daltons a single trifluoroacetate at 114 is over 26 percent of the associated mass, among the largest corrections in this catalogue. Calculate from net peptide content rather than the vial label.
How does it differ from Bronchogen?
By tissue layer. Bronchogen is assigned to bronchial tissue itself, Chonluten to lung and bronchial mucosa, meaning the epithelial lining rather than the structural tissue.
Is that distinction well supported?
It rests on the fractionation source rather than on demonstrated localisation. Asserting mucosal specificity as distinct from tissue specificity is a finer claim than any study in this literature currently supports.
What endpoints have been measured?
Respiratory tissue observations in aged rodent models including histology and gene-expression markers, plus family-wide cell-culture work on chromatin decondensation. The primary record here is thinner than for Epitalon or Vilon.
Are sublingual figures comparable with injectable ones?
No. Sublingual preparations appear specifically in the Chonluten literature as lingual drops, and figures from that route cannot be compared with parenteral amounts without accounting for absorption.
Compliance Statement
Chonluten peptide is sold exclusively for laboratory research use. It is not a drug, food, or cosmetic product, and it is not a dietary product of any kind. It is not approved by the FDA or any comparable authority for human or veterinary use, its proposed mechanism has not been independently established, and amounts cited are figures from published studies in the species those studies used. This product is not intended to diagnose, treat, cure, or prevent any disease. It must not be given to humans or animals. Purchase is restricted to qualified researchers and institutions operating within applicable laws. All handling is the responsibility of the purchasing laboratory.
Other formats of Chonluten
Chonluten is also stocked as Chonluten 20mg Nasal Spray and Chonluten 20mg preloaded 3ml pen. Each listing states its own quantity and concentration, and the pen and vial comparison explains what changes between formats.
19 reviews for Chonluten Peptide 20mg